Covid-19 Impact on the Breast Lesion Localization Methods Market

The breast lesion localization methods market is not expected to be impacted greatly by the Covid-19 pandemic in 2020-2021. However, routine breast cancer screening at hospitals and annual screening programs have been suspended in many countries in order to maintain social distancing protocols and minimize patient flow in health care centers. Moreover, non-essential procedures and surgeries have been postponed for the post lockdown period which could have a slight impact on the market only for Q1 and Q2 of 2020 in most regions. Breast lesion localization methods market.

Market Size

[157 Pages Report] The breast lesion localization methods market is expected to grow from 3,974.4 thousands of procedures in 2020 to 5750.9 thousands of procedures by 2025, at a CAGR of 7.5% during the forecast period.

The growth of this market is primarily driven by factors such as the rising incidence of breast cancer, an increasing number of breast cancer surgeries, and growing awareness on the early detection of breast cancer.

Download a PDF Brochure @ www.marketsandmarkets.com/pdfdownloadNew.asp?id=35768623

What drives the Market?

  • Growing Incidence of Breast Cancer
  • Increasing Number of Breast Cancer Surgeries
  • Increasing Awareness On The Early Detection Of Breast Cancer

However, the uncertain regulatory approval process faced by prominent players is hampering the growth of the breast lesion localization methods market.

Wire localization accounted for the largest share in the market in the forecast period.

The wire localization segment accounted for the highest share of the procedures market, by type. The large share of this segment is attributed to its accuracy in abnormal tissue localization, minimal removal of normal tissues, minimal scarring, and availability of reimbursement for breast lesion localization devices. The ease of use of wire localization technology and the familiarity of end users with the technology have resulted in its increased adoption.

Request a Sample Pages @ www.marketsandmarkets.com/requestsampleNew.asp?id=35768623

Sentinel lymph node identification expected to show the highest growth rate in the forecast period.

On the basis of usage, the breast lesion localization methods market is segmented into tumor identification and sentinel lymph node identification. The sentinel lymph node identification segment is expected to grow at the fastest rate in the forecast period, Growth in this segment can be attributed to the increase in acceptance of SLNB as a first-line diagnostic approach for breast cancer staging, as it is more sensitive and causes less morbidity than traditional techniques for the early staging of breast cancer.

The Asia Pacific region holds the largest share in the market during the forecast period of 2020–2025.

Geographically, the breast lesion localization methods market is segmented into North America, Europe, the Asia Pacific and Rest of the World. The large share of the Asia Pacific region is due to improving healthcare infrastructure, high government spending on breast cancer research, and rising awareness about the importance of the early detection of breast cancer in several APAC countries. Moreover, increasing focus of prominent players on emerging Asian countries will further support the growth of the market in this region.

Breast Lesion Localization Methods Market Key Market Players

The key players operating in the breast lesion localization methods market include Becton, Dickinson and Company (US), Endomagnetics Limited (UK), SOMATEX Medical Technologies GmbH (Germany), Cianna Medical (US), Leica Biosystems (US) and IZI Medical Products (US).

Speak to Analyst @ www.marketsandmarkets.com/requestsampleNew.asp?id=35768623

Recent Developments:

  • In 2019, Hologic Inc. (US) launched LOCalizer wire-free guidance system.
  • In 2019, Argon Medical Devices (US) acquired Mana-Tech, Ltd. (UK) enabling Argon to distribute its products across UK and Ireland.
  • In 2019, IZI Medical Products, LLC acquired Cook’s acquired product portfolio of soft tissue biopsy and breast localization needle assets to enable it to capture newer markets.

Leave a Reply

Your email address will not be published. Required fields are marked *